Author

Patricia Kellie Turner

Institution: Eli Lilly (United States)

Observed institution: Eli Lilly (United States)

OpenAlex ID: A5105194185

Assessment of concentrations of abemaciclib and its major active metabolites in plasma, CSF, and brain tumor tissue in patients with brain metastases secondary to hormone receptor positive (HR+) breast cancer.

2016 · Solmaz Sahebjam, Emilie Le Rhun, et al. · Journal of Clinical Oncology · 22

First-in-human dose escalation study of LY2875358 (LY), a bivalent MET antibody, as monotherapy and in combination with erlotinib (E) in patients with advanced cancer.

2013 · Jonathan Wade Goldman, Lee S. Rosen, et al. · Journal of Clinical Oncology · 16

Abstract CT237: Interim results of a first-in-human phase 1 study of the oral MET kinase inhibitor, LY2801653, in patients with advanced cancer

2014 · Jimmy Hwang, Roger Cohen, et al. · Cancer Research · 1

Works count: 3

Citation count: 39

H-index: 2

I10-index: 2